drugset
drugset / Trial / NCT02017457

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

NCT02017457 ↗

Phase 2 Completed 50 enrolled Carlos Graux, MD, PhD Belgian Hematological Society · collabCelgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

The present project is a multicenter, phase II trial which aims at evaluating if the administration of azacytidine (Vidaza®) combined to donor lymphocyte infusion (DLI) could improve the response rate to DLI in the population of patients with relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem cell transplantation.

Timeline

Start
2013-12
Primary completion
2019-11
Completion
2019-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacytidine Other / unclassified 35 mg/m2 Subcutaneous

Indications

acute myeloid leukemia myelodysplastic syndrome